Condition: Advanced Solid Tumor · Sponsor: EMD Serono Research & Development Institute, Inc.
The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months
This description comes directly from the study's public registry record.
US Medical Information · 888-275-7376 · eMediUSA@emdserono.com
Communication Center · +49 6151 72 5200 · service@emdgroup.com
Always discuss trial participation with your own doctor first.
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - Memorial Sloan Kettering Cancer Center (CC)- Westc | New York, New York, United States | Withdrawn |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| UZ Leuven | Leuven, Belgium | Recruiting |
| Institut Bergonié - Service d'Oncologie Médicale | Bordeaux, France | Recruiting |
| Centre Oscar Lambret - cancerologie generale | Lille, France | Recruiting |
| Centre Leon Berard - Service d'Oncologie Medicale | Lyon, France | Recruiting |
| Centre Antoine Lacassagne - Service d'Hématologie Oncologie | Nice, France | Recruiting |
| National Cancer Center Hospital | Chūōku, Japan | Recruiting |
| Universitaetsspital Zuerich - Klinik fuer Neurologie | Zurich, Switzerland | Recruiting |
| Royal Marsden Hospital-Sutton - Dept of Oncology (Surrey) | Sutton, Surrey, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06641908